MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412775 | Name: Cgs 26393

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cgs 26393 is a prodrug of CGS-26303.

Chemical Structure

Cgs 26393
Cgs 26393
CAS#154116-34-4

Theoretical Analysis

MedKoo Cat#: 412775

Name: Cgs 26393

CAS#: 154116-34-4

Chemical Formula: C28H26N5O3P

Exact Mass: 511.1773

Molecular Weight: 511.52

Elemental Analysis: C, 65.75; H, 5.12; N, 13.69; O, 9.38; P, 6.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Cgs 26393; Cgs26393; Cgs-26393
IUPAC/Chemical Name
Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, diphenyl ester, (S)-
InChi Key
AHIFMZUYRNPRJK-MHZLTWQESA-N
InChi Code
InChI=1S/C28H26N5O3P/c34-37(35-25-12-6-2-7-13-25,36-26-14-8-3-9-15-26)21-29-27(28-30-32-33-31-28)20-22-16-18-24(19-17-22)23-10-4-1-5-11-23/h1-19,27,29H,20-21H2,(H,30,31,32,33)/t27-/m0/s1
SMILES Code
O=P(CN[C@H](C1=NN=NN1)CC2=CC=C(C3=CC=CC=C3)C=C2)(OC4=CC=CC=C4)OC5=CC=CC=C5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 511.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dai ZK, Hsieh CC, Chai CY, Wu JR, Jeng AY, Chou SH, Wu BN, Yeh JL, Chen IJ, Tan MS. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat. Pediatr Pulmonol. 2010 Nov;45(11):1076-85. doi: 10.1002/ppul.21290. PMID: 20658482. 2: Kwan AL, Lin CL, Chang CZ, Winardi D, Yen CP, Wu SC, Lee KS, Kassell NF, Howng SL, Savage P, Jeng AY. Oral administration of an inhibitor of endothelin- converting enzyme attenuates cerebral vasospasm following experimental subarachnoid haemorrhage in rabbits. Clin Sci (Lond). 2002 Aug;103 Suppl 48:414S-417S. doi: 10.1042/CS103S414S. PMID: 12193135. 3: Trapani AJ, De Lombaert S, Kuzmich S, Jeng AY. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S69-71. PMID: 8587471. 4: Yap EY, Battistini B, McKay KO. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi. Br J Pharmacol. 2000 Jan;129(1):170-6. doi: 10.1038/sj.bjp.0703006. PMID: 10694217; PMCID: PMC1621126. 5: Pelletier S, Battistini B, Jeng AY, Sirois P. Effects of dual endothelin- converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleukin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S10-2. doi: 10.1097/00005344-199800001-00005. PMID: 9595386. 6: Watts SW, Thakali K, Smark C, Rondelli C, Fink GD. Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol. 2007 Nov- Dec;47(5-6):302-12. doi: 10.1016/j.vph.2007.08.006. Epub 2007 Sep 7. PMID: 17904426; PMCID: PMC2719821. 7: Kwan AL, Lin CL, Chang CZ, Winardi D, Yen CP, Howng SL, Jeng AY. Effects of endothelin-converting enzyme inhibitors on hemolysate-induced morphological changes and production of endothelin-1 in bovine cerebrovascular endothelial cells. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S160-2. doi: 10.1097/00005344-200036051-00050. PMID: 11078366. 8: Pham D, Jeng AY, Plante S, Escher E, Battistini B. Inhibition of endothelin- converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery. Can J Physiol Pharmacol. 2002 May;80(5):450-7. doi: 10.1139/y02-059. PMID: 12056552. 9: Goto K. [Prospects for endothelin-related drugs]. Nihon Rinsho. 2004 Sep;62 Suppl 9:673-81. Japanese. PMID: 15506472. 10: Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, Warner TD. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol. 1999 May;55(5):902-9. PMID: 10220569.